Join to View Full Profile
300 Pasteur DrStanford, CA 94305
Phone+1 650-498-5710
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 3 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Joseph Belanoff, MD is a board certified psychiatrist in Stanford, California. He is currently licensed to practice medicine in California.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityResidency, Psychiatry, 1992 - 1996
Columbia University Vagelos College of Physicians and SurgeonsClass of 1992
Certifications & Licensure
CA State Medical License 1993 - 2027
American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- 6 citationsBiochemical and Radiological Changes in Liver Steatosis Following Mifepristone Treatment in Patients With HypercortisolismJohn C. Parker, Andreas G. Moraitis, Joseph K. Belanoff
AACE Clinical Case Reports. 2021-07-12 - 25 citationsInsights into the Therapeutic Potential of Glucocorticoid Receptor Modulators for Neurodegenerative DiseasesAlejandro F. De Nicola, Maria Meyer, Rachida Guennoun, Michael Schumacher, Hazel Hunt
International Journal of Molecular Sciences. 2020-03-20 - 21 citationsLong-term effects of the glucocorticoid receptor modulator CORT113176 in murine motoneuron degeneration.Maria Meyer, Maria Sol Kruse, Laura Garay, Analia Lima, Paulina Roig
Brain Research. 2020-01-15
Press Mentions
Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with HypercortisolismDecember 31st, 2025- Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian CancerOctober 14th, 2025
- Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian CancerJuly 14th, 2025
